Spine Innovations Marks Milestone — Over 20,000 ESP Spinal Discs Implanted — as Global Demand Grows
Since its formation as a wholly independent company in late 2020, Spine Innovations has continued to expand sales of its ESP spinal disc replacements, with more than 20,000 prostheses successfully implanted in patients around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005394/en/
CP-ESP cervical disc prosthesis LP-ESP lumbar disc prosthesis (Photo: Spine Innovations)
At the same time, Spine Innovations continues to expand its market reach. The company is now active in 17 countries, including new markets within Europe that opened in 2021. It will expand into Central and South America, including Mexico and Brazil, as well as additional European countries, including Norway and the Netherlands. In 2022, Spine Innovations is also working toward FDA approval to enter the US market.
Spine Innovations’ growth has been energized by operating like a startup and hyper-specializing in total spinal disc replacement and the preservation of natural motion. The company’s Cervical Prosthesis (CP-ESP®) and Lumbar Prosthesis (LP-ESP®) utilize a viscoelastic design — recognized as the latest generation of disc replacement — to mimic the function and range of movements of a natural disc and allow the spine to behave naturally.
Increasing, widespread interest in ESP disc replacements, and their swift acceptance by orthopedic surgeons, neurosurgeons, and patients, highlight the strong desire for products that can restore health and quality of life.
ESP discs combine two titanium end plates with an elastomeric cushion made of polycarbonate urethane. This structure imitates the natural disc, in which bony segments are connected by a spongy disc that provides flexibility while withstanding the pressures of compression and torsion. Specific features of the end plates — short spikes, a rough outer surface, and a coating of hydroxyapatite (HA), which is proven to enhance bone ingrowth — help to ensure stability and bony fixation of the implant over time.
“With the ESP, the patients gain a counter force which is similar to what the natural disc provides and reduces risks of facet pain.” Dr. Svante Berg from Stockholm, Sweden, says Remobilization of the disc space with too much mobility can lead to such side effect.
Pr. Jean Yves Lazennec of Pitie-Salpetriere Hospital in Paris says, “The ESP discs reproduce the natural center of rotation and adapt when the patient is aging.”
The entire team of Spine Innovations is focused on satisfying growing market demand. Sandrine Carle President, says “More and more surgeons are choosing to replace degenerative discs with prostheses that can maintain spinal motion instead of fusing the segment. ESP disc replacements provide that solution by replicating natural disc motion and enabling the entire spine to behave as normally as possible.”
---------------------------------------------
Based in Heimsbrunn (France), Spine Innovations continues to increase market penetration and aims to become a leading actor in the total disc replacement worldwide market with its patented viscoelastic technology used in the ESP discs. To learn more, please visit www.spine-innovations.com and www.esp-disc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005394/en/
Contact information
For more information, contact:
Eric Hermann
Sales and Marketing Director
Directeur Marketing et Commercial
SPINE INNOVATIONS
Email: e.hermann@spine-innovations.com
Cell : +33 6 14 28 82 30
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
